Neoadjuvant immunochemotherapy versus chemotherapy for elderly patients with IB–IIIB non-small-cell lung cancer in real-world practice

Neoadjuvant immunochemotherapy versus chemotherapy for elderly patients with IB–IIIB non-small-cell lung cancer in real-world practice

Abstract Background Immunochemotherapy is currently the standard treatment plan for non-small-cell lung cancer (NSCLC) patients with no driver gene mutations. However, it is uncertain whether immunochemotherapy is effective or safe for elderly patients (≥ 65 years). Therefore, this study compared pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongfeng Shuai, Jiacong Liu, Yuhong Yang, Xuhua Huang, Jiayue Ye, Linhai Zhu, Jian Hu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Non-small-cell lung cancer (NSCLC)
Elderly patients (≥ 65 years)
Neoadjuvant treatment
Immunochemotherapy
Chemotherapy
Online Access:https://doi.org/10.1186/s12885-025-14545-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14545-7

Similar Items